Vitrasert intraocular implant delivering ganciclovir into the eye data

CHIR (Emeryville, Calif.) announced that final results of its Phase III trial have demonstrated that the intraocular insert delays progression of CMV retinitis compared to intravenous ganciclovir.

The completed analysis shows essentially the same results as an interim analysis released in January. The downsides of the treatment - blurred vision in the first few days following the implant's placement, and loss of visual acuity for several weeks - has not changed, said spokesperson Larry Kurtz. ...